Fosun Hongchuang

Fosun Hongchuang is a clinical-stage biopharmaceutical company based in Suzhou, China, focused on the discovery and development of innovative small molecule therapeutics for oncology and rare diseases. Founded as a joint venture between Fosun Pharma and Dr. Zhenghong Xu, the company leverages a deep understanding of cancer biology to target key signaling pathways. Its lead programs include FCN-159, a highly selective MEK inhibitor being evaluated for neurofibromatosis type 1 and various solid tumors, and FCN-437, a CDK4/6 inhibitor for breast cancer. The company's pipeline also features inhibitors targeting BTK and BCL-2 for hematological malignancies. Fosun Hongchuang aims to address significant unmet medical needs through precision medicine and efficient R&D processes within the broader Fosun Pharma ecosystem. The firm operates primarily out of the Suzhou Biobay industrial park, benefiting from a robust local biotech infrastructure.